Hepatocellular carcinoma tumour markers: Current role and expectations

Nicole Rich, Amit G. Singal

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Tumour markers could be helpful along the continuum of care for patients with hepatocellular carcinoma; however, there is insufficient data for routine use of most current biomarkers in clinical practice. Therefore, the backbone of early detection, diagnosis and treatment response for hepatocellular carcinoma remains imaging-based. Alpha fetoprotein is the best studied of all biomarkers and may be of benefit for early detection when used in combination with ultrasound. Several other biomarkers, including AFP-L3, DCP, osteopontin, and GP73, are also being evaluated for early detection of hepatocellular carcinoma in phase III biomarker studies. Serum and tissue-based biomarkers and genomics may aid in HCC diagnosis, prognosis, and treatment selection; however, further studies are needed to better characterize their accuracy and potential role in clinical practice.

Original languageEnglish (US)
Pages (from-to)843-853
Number of pages11
JournalBest Practice and Research: Clinical Gastroenterology
Volume28
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Tumor Biomarkers
Hepatocellular Carcinoma
Biomarkers
Osteopontin
Continuity of Patient Care
alpha-Fetoproteins
Genomics
Early Diagnosis
Therapeutics
Serum

Keywords

  • Alpha fetoprotein
  • Early detection
  • Hepatocellular carcinoma
  • Tumour markers

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Hepatocellular carcinoma tumour markers : Current role and expectations. / Rich, Nicole; Singal, Amit G.

In: Best Practice and Research: Clinical Gastroenterology, Vol. 28, No. 5, 2014, p. 843-853.

Research output: Contribution to journalArticle

@article{a571762af9594fb79cbd06ca5510a6de,
title = "Hepatocellular carcinoma tumour markers: Current role and expectations",
abstract = "Tumour markers could be helpful along the continuum of care for patients with hepatocellular carcinoma; however, there is insufficient data for routine use of most current biomarkers in clinical practice. Therefore, the backbone of early detection, diagnosis and treatment response for hepatocellular carcinoma remains imaging-based. Alpha fetoprotein is the best studied of all biomarkers and may be of benefit for early detection when used in combination with ultrasound. Several other biomarkers, including AFP-L3, DCP, osteopontin, and GP73, are also being evaluated for early detection of hepatocellular carcinoma in phase III biomarker studies. Serum and tissue-based biomarkers and genomics may aid in HCC diagnosis, prognosis, and treatment selection; however, further studies are needed to better characterize their accuracy and potential role in clinical practice.",
keywords = "Alpha fetoprotein, Early detection, Hepatocellular carcinoma, Tumour markers",
author = "Nicole Rich and Singal, {Amit G.}",
year = "2014",
doi = "10.1016/j.bpg.2014.07.018",
language = "English (US)",
volume = "28",
pages = "843--853",
journal = "Bailliere's Best Practice and Research in Clinical Gastroenterology",
issn = "1521-6918",
publisher = "Bailliere Tindall Ltd",
number = "5",

}

TY - JOUR

T1 - Hepatocellular carcinoma tumour markers

T2 - Current role and expectations

AU - Rich, Nicole

AU - Singal, Amit G.

PY - 2014

Y1 - 2014

N2 - Tumour markers could be helpful along the continuum of care for patients with hepatocellular carcinoma; however, there is insufficient data for routine use of most current biomarkers in clinical practice. Therefore, the backbone of early detection, diagnosis and treatment response for hepatocellular carcinoma remains imaging-based. Alpha fetoprotein is the best studied of all biomarkers and may be of benefit for early detection when used in combination with ultrasound. Several other biomarkers, including AFP-L3, DCP, osteopontin, and GP73, are also being evaluated for early detection of hepatocellular carcinoma in phase III biomarker studies. Serum and tissue-based biomarkers and genomics may aid in HCC diagnosis, prognosis, and treatment selection; however, further studies are needed to better characterize their accuracy and potential role in clinical practice.

AB - Tumour markers could be helpful along the continuum of care for patients with hepatocellular carcinoma; however, there is insufficient data for routine use of most current biomarkers in clinical practice. Therefore, the backbone of early detection, diagnosis and treatment response for hepatocellular carcinoma remains imaging-based. Alpha fetoprotein is the best studied of all biomarkers and may be of benefit for early detection when used in combination with ultrasound. Several other biomarkers, including AFP-L3, DCP, osteopontin, and GP73, are also being evaluated for early detection of hepatocellular carcinoma in phase III biomarker studies. Serum and tissue-based biomarkers and genomics may aid in HCC diagnosis, prognosis, and treatment selection; however, further studies are needed to better characterize their accuracy and potential role in clinical practice.

KW - Alpha fetoprotein

KW - Early detection

KW - Hepatocellular carcinoma

KW - Tumour markers

UR - http://www.scopus.com/inward/record.url?scp=84916631830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916631830&partnerID=8YFLogxK

U2 - 10.1016/j.bpg.2014.07.018

DO - 10.1016/j.bpg.2014.07.018

M3 - Article

C2 - 25260312

AN - SCOPUS:84916631830

VL - 28

SP - 843

EP - 853

JO - Bailliere's Best Practice and Research in Clinical Gastroenterology

JF - Bailliere's Best Practice and Research in Clinical Gastroenterology

SN - 1521-6918

IS - 5

ER -